Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Traws Pharma, Inc. has announced the engagement of KPMG LLP as its new independent registered public accounting firm, effective from Monday. This change comes as the pharmaceutical company, previously known as Onconova Therapeutics (NASDAQ:TRAW), prepares for its fiscal year ending December 31, 2024.
The decision, made by the Audit Committee of the Board of Directors on Monday, marks a significant transition for the Delaware-incorporated company, which specializes in pharmaceutical preparations. The appointment follows a period during which Traws Pharma did not consult with KPMG on any accounting principles or auditing matters that would be significant in their financial reporting.
Notably, throughout fiscal years 2023 and 2022, and up until the recent change, there had been no disagreements or reportable events between Traws Pharma and KPMG that would require disclosure under SEC regulations.
In accordance with SEC requirements, Traws Pharma has obtained a letter from its former auditor, Ernst and Young LLP, confirming their agreement with the statements made regarding their engagement. This letter, dated today, has been filed with the SEC and is included as an exhibit in the Form 8-K filing.
The Nasdaq-listed company, trading under the symbol NASDAQ:TRAW, is headquartered in Newtown, PA, and operates under the leadership of Chief Financial Officer Mark Guerin.
This transition in certifying accountant comes as part of Traws Pharma's ongoing efforts to maintain robust financial practices and transparency with its stakeholders. The information regarding this change is based on the company's recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.